Development Pipeline

View the status of our current development pipeline as of April 24, 2019.

Development Pipeline (all disease areas) [PDF 234KB]

Oncology

Development code Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin Overseas name
(Collaborator)
Mode of Action
RG7446 Non-small cell lung cancer
(NSCLC) [1st line] #
Approved
(18/12)
atezolizumab
Tecentriq®
Injection
Roche
Tecentriq®
Engineered anti-PDL1 monoclonal antibody
Small cell lung cancer
#
Filed
(18/12)
Breast cancer
#
Filed
(18/12)
NSCLC (adjuvant)
#
Phase III
Multinational study
Urothelial carcinoma
#
Phase III
Multinational study
Muscle invasive urothelial carcinoma (adjuvant) # Phase III
Multinational study
Renal cell carcinoma
#
Phase III
Multinational study
Renal cell carcinoma (adjuvant)
#
Phase III
Multinational study
Early breast cancer
#
Phase III
Multinational study
Ovarian cancer
#
Phase III
Multinational study
Prostate cancer
#
Phase III
Multinational study
Hepatocellular carcinoma
#
Phase III
Multinational study
Head and neck carcinoma (adjuvant)
#
Phase III
Multinational study
RG6268 Solid tumors [NTRK fusion-positive] Filed
(18/12)
entrectinib
 
Oral
Roche / Nerviano Medical Sciences ROS1/TRK inhibitor
NSCLC Filed
(19/03)
RG435 Renal cell carcinoma
#
Phase III
Multinational study
bevacizumab
Avastin®
Injection
Roche
Avastin®
Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody
Hepatocellular carcinoma
#
Phase III
Multinational study
RG3502 Breast cancer (adjuvant)
#
Phase III
Multinational study
trastuzumab emtansine
Kadcyla®
Injection
Roche
Kadcyla®
Anti-HER2 antibody-tubulin polymerization inhibitor conjugate
RG7440 Prostate cancer Phase III
Multinational study
ipatasertib

Oral
Roche/Array BioPharma AKT inhibitor
Breast cancer Phase III
Multinational study
RG7596 Diffuse large B-cell lymphoma
(DLBCL)
Phase III
Multinational study
polatuzumab vedotin

Injection
Roche Anti-CD79b antibody-drug conjugate
RG6264 Breast cancer
(Fixed-dose combination, subcutaneous injection)
Phase III
Multinational study
trastuzumab/pertuzumab
Herceptin® / Perjeta®
Injection
Roche
Herceptin® / Perjeta®
Anti-HER2 humanized monoclonal antibody/ HER2 dimerization inhibitory humanized monoclonal antibody
AF802 / RG7853 NSCLC (adjuvant)
#
Phase III
Multinational study
alectinib
Alecensa®
Oral
In-house
Alecensa®
(Roche)
ALK inhibitor
GC33 Hepatocellular carcinoma Phase I
Multinational study*
codrituzumab
 
Injection
In-house Anti-Glypican-3 humanized monoclonal antibody
CKI27 Solid tumors Phase I

Oral
In-house Raf and MEK dual inhibitor
ERY974 Solid tumors Phase I

Injection
In-house Anti-Glypican-3/CD3 bispecific antibody
RG7421 Solid tumors Phase I cobimetinib

Oral
Roche/Exelixis
Cotellic®
MEK inhibitor
RG7802 Solid tumors Phase I cibisatamab

Injection
Roche Anti-CEA/CD3 bispecific antibody
RG7828 Hematologic tumors Phase I mosunetuzumab

Injection
Roche Anti-CD20/CD3 bispecific antibody

* Multinational studies managed by Chugai

Bone and Joint Diseases

Development code Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
ED-71 Osteoporosis Filed
(18/02)
China
eldecalcitol
Edirol®
Oral
In-house Activated vitamin D3 agent
NRD101 Knee osteoarthritis
/Shoulder periarthritis
Phase III
China
purified sodium hyaluronate
Suvenyl®
Injection
In-house Sodium hyaluronate

Renal Diseases

Development code Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
EOS789 Hyperphosphatemia Phase I

Oral
In-house -

Autoimmune Diseases

Development code Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
MRA/RG1569 Systemic sclerosis
#
Phase III
Multinational study
tocilizumab
Actemra®
Injection
In-house
Actemra®/ RoActemra® (EU)
(Roche)
Humanized anti-human IL-6 receptor monoclonal antibody
RG7845 Rheumatoid arthritis Phase I fenebrutinib

Oral
Roche BTK inhibitor

Neurology

Development code Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG1450 Alzheimer’s disease Phase III
Multinational study
gantenerumab

Injection
Roche/MorphoSys Anti-amyloid-beta human monoclonal antibody
SA237 / RG6168 Neuromyelitis optica spectrum disorder (NMOSD) Phase III
Multinational study*
satralizumab

Injection
In-house

(Roche)
Anti-IL-6 receptor recycling antibody
RG6042 Huntington’s disease Phase III
Multinational study


Injection
Roche/Ionis Pharmaceuticals Antisense oligonucleotide targeting HTTmRNA
RG6206 Duchenne muscular dystrophy (DMD) Phase II/III
Multinational study


Injection
Roche/Bristol-Myers Squibb Anti-myostatin adnectin
RG7916 Spinal muscular atrophy (SMA) Phase II/III
Multinational study
risdiplam

Oral
Roche/PTC Therapeutics SMN2 splicing modifier
RG7935 Parkinson’s disease Phase I prasinezumab

Injection
Roche/Prothena Anti-α-synuclein monoclonal antibody
GYM329 / RG6237 Neuromuscular disease Phase I

Injection
In-house

(Roche)
RG7906 Psychiatric disorders Phase I

Oral
Roche

RG6100 Alzheimer’s disease Phase I

injection
Roche/AC Immune Anti-tau humanized monoclonal antibody
RG7412 Alzheimer’s disease Development
discontinued
crenezumab

Injection
Roche/AC Immune Anti-amyloid-beta humanized monoclonal antibody

* Multinational studies managed by Chugai

Other diseases

Development code Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
ACE910/RG6013 Hemophilia A
(Non-inhibitor)
#
Approved
(18/12)
Japan
emicizumab
Hemlibra®
Injection
In-house
Hemlibra®
(Roche)
Anti-FIXa/FX bispecific antibody
Approved
(19/03)
Europe
RG7716 Diabetic macular edema Phase III
Multinational study
faricimab

Injection
Roche Anti-VEGF/Ang2 bispecific antibody
Wet age-related macular degeneration Phase III
Multinational study
CIM331** Pruritus in dialysis patients Phase II nemolizumab
 
Injection
In-house
 
Anti-IL-31 receptor A humanized monoclonal antibody
SKY59/RG6107 Paroxysmal nocturnal hemoglobinuria
(PNH)
Phase I/II
Multinational study
crovalimab
 
Injection
In-house
 
(Roche)
Anti-C5 recycling antibody
PCO371 Hypoparathyroidism Phase I  
 
Oral
In-house PTH1 receptor agonist
AMY109 Endometriosis Phase I  
 
Injection
In-house -

** Development for atopic dermatitis: Out-licensed to Galderma (Overseas) and Maruho (Japan)

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

  • Like
  • Tweet
  • LINE it!
  • E-mail

Reports & Downloads

Back to top